In vitro data: Talidox® shows similar cell killing activity compared to free doxorubicin
The cell killing activity of 100 μg/ml doxorubicin was measured on human uterine sarcoma cells in vitro in a cytotoxicity study. The cytotoxic effect of 100 μg/ml free doxorubicin (Adriblastin) was compared to 100 μg/ml doxorubicin formulated as Doxil® and 100 μg/ml doxorubicin in form of Talidox®. Liposomes without encapsulated doxorubicin served as a positive control in order to demonstrate the safety of the lipid layer.
As demonstrated in the graph, free doxorubicin already kills cancer cells very efficiently at this concentration. Doxil®, which is indicated for the treatment of ovarian cancer, does not release the drug very effectively. The release mechanism of Talidox® however, results in similar cytotoxic activity of Talidox® compared to free doxorubicin. This effect is independent of any targeting function, because the experiments were not conducted under inflammatory conditions.
With regard to the in vitro release of the active drug, Talidox® proves to be more effective compared to Doxil® and kills cancer cells similarly efficiently at a doxorubicin concentration of 100 μg/ml as free doxorubicin.